| Literature DB >> 24192444 |
Mustafa Tarık Ağaç1, Levent Korkmaz, Hüseyin Bektas, Zeydin Acar, Hakan Erkan, Ibrahim Halil Kurt, Adem Adar, Sükrü Celik.
Abstract
OBJECTIVE: To investigate the presence of myocardial fibrosis determined by fragmented QRS in patients with severe aortic valve stenosis. SUBJECTS AND METHODS: Eighty-seven consecutive patients with severe aortic valve stenosis and 83 age- and gender-matched control subjects were enrolled into this study. Severe aortic valve stenosis was defined as an aortic valve area <1 cm(2), a Vmax >4 m/s, or a mean gradient ≥40 mm Hg. Fragmented QRS was assessed using a 12-lead electrocardiogram.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24192444 PMCID: PMC5586837 DOI: 10.1159/000355474
Source DB: PubMed Journal: Med Princ Pract ISSN: 1011-7571 Impact factor: 1.927
Fig. 1Examples ofvarious fQRS patterns. The arrows show fQRS in lead III, AVF and AVL in a patient with severe aortic stenosis. Note that QRS morphology is not compatible with the typical bundle branch block pattern and the duration is <120 ms.
Clinical and laboratory characteristics of the patients and control subjects
| Variables | Control group (n = 83) | Patient group (n = 87) | p |
|---|---|---|---|
| Age, years | 75 ± 9 | 76 ± 7 | n.s. |
| Male gender | 36 (43) | 30 (35) | n.s. |
| Hypertension | 33 (40) | 51 (59) | 0.02 |
| Diabetes | 5 (6) | 12 (14) | n.s. |
| Smoking | 17 (20) | 11 (13) | n.s. |
| Hypercholesterolemia | 9 (11) | 13 (15) | n.s. |
| fQRS | 15 (18) | 40 (46) | <0.001 |
| Cardiovascular medications | |||
| ASA | 3 (4) | 6 (7) | n.s. |
| β-Blockers | 10 (12) | 13 (15) | n.s. |
| Cholesterol-lowering drugs | 7 (8) | 8 (9) | n.s. |
| ACEI or ARB | 14 (17) | 29 (33) | 0.01 |
Values are presented as numbers (%) unless otherwise stated. ACEI = Angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ASA = acetylsalicylic acid; n.s. = not significant.
Clinical and laboratory characteristics of subjects with or without fQRS
| Variables | fQRS (−) (n = 115) | fQRS (+) (n = 55) | p |
|---|---|---|---|
| Age, years | 75 ± 8 | 76 ± 7 | n.s. |
| Male gender | 48 (42) | 18 (33) | n.s. |
| Hypertension | 52 (45) | 32 (58) | n.s. |
| Diabetes | 9 (8) | 8 (15) | n.s. |
| Smoking | 22 (19) | 6 (11) | n.s. |
| Hypercholesterolemia | 15 (13) | 7 (13) | n.s. |
| Aortic stenosis | 47 (41) | 40 (73) | <0.001 |
| Cardiovascular medications | |||
| ASA | 7 (6) | 2 (4) | n.s. |
| β-Blockers | 16 (14) | 7 (13) | n.s. |
| Cholesterol-lowering drugs | 10 (9) | 5 (9) | n.s. |
| ACEI or ARB | 26 (23) | 17 (31) | n.s. |
Values are presented as numbers (%) unless otherwise stated. ACEI = Angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; ASA = acetylsalicylic acid; n.s. = not significant.